Undisclosed ADC-2 / Transcenta - LARVOL DELTA

Preclinical characterization of novel LIV1 antibody drug conjugates (AACR 2026) - "After conjugation into ADCs, the T1/2 of 48D6 ADC-2 ranged 10.4~11.6 days while that of SGN-LIV1A analog in mice is 3.7~3.9 days. LIV1 targeting ADC-2 and ADC-3 exhibited strong anti-tumor activities as monotherapy in PDX models and the anti-tumor activity is further enhanced by checkpoint inhibitor. ADC-2 displayed excellent tolerability profile in mice. These results support further investigation of our LIV1 ADCs in LIV1 positive solid tumors."

ADC • IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • PD-L1

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS (PRNewswire) - "Transcenta Holding Limited...announced late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer Symposium (SABCS)....Although ADC-1 and ADC-2 displayed similar and specific cytotoxic activities against human LIV-1-expressing tumor cells in vitro, as compared to SGN-LIV1A analog (DAR4) or ADC-3, they exhibited much higher maximal tumor cell killing than SGN-LIV1A analog in vivo. In addition, both ADC-1 and ADC-2 demonstrated a strong bystander effect which is important to overcome tumor heterogeneity. In vivo pharmacology study revealed that ADC-1 or ADC-2 exhibited dose-dependent and more potent anti-tumor activities than the SGN-LIV1A analog or ADC-3 in the human LIV-1 transfected MDA-MB-468, a TNBC tumor model."

Preclinical • Triple Negative Breast Cancer